The Parexel Podcast | Episode 15: Pandemic preparedness: Investing in the future of infectious disease vaccine development

Drug Development for Rare Disease and Oncology During the COVID-19 Pandemic

How COVID-19 Testing Demand Threw off Thermo Fisher’s Acquisition of Qiagen

About the Authors Aaron Dy, Ph.D. is a Senior Analyst in the Health Advances...

Biopharma R&D in the Post-COVID World

About the Authors Steven Chang, Ph.D. is a Senior Analyst in the Health...

eBook: Biopharma in the COVID-19 World

The Special Approval Pathway (SAP) for COVID-19 related products in China

The regulatory pathway for COVID-19 drugs in China is governed by the Special Approval Program (SAP) which was introduced by National Medical Product Administration (NMPA) in 2005.  SAP is...

NMPA Guidance on the Management of Clinical Trials during the COVID-19 from July 2020

Conducting clinical trials during the COVID-19 pandemic has produced many challenges globally. The initiation, conduct, implementation and completion of a trial during this time requires special...

Against All Odds: Can Covid-19 Usher in a New Era in International Public Health Cooperation?

Key Takeaways The COVID-19 pandemic has drawn attention to international efforts to promote...

The New Pragmatism: Clinical Trials, Investment and Regulations Post-COVID-19

Once the COVID-19 pandemic passes or is contained, the world will look and work very differently. The biopharmaceutical industry is no exception. In this podcast, Peyton Howell, Parexel’s Chief...

Demystifying SARS-CoV-2 Testing for COVID-19 (Third Edition – Part 1: Updates and Trends)

Click here to download the full presentation. SummaryAs the world continues to battle...

FDA Expectations for Responding to Employees in Pharmaceutical Manufacturing Infected with COVID-19

Global manufacturers and regulators are facing new challenges during the SARS-CoV-2 pandemic to maintain supply chains, and avoid shortages, of drugs, biologics and medical devices.  Numerous...

eBook: Digital Health and the Global Pandemic

Using risk assessment decision tree models to maintain safety and data validity in clinical trials during COVID-19

During the COVID-19 pandemic, challenges to the conduct of clinical trials may arise, e.g. due to travel restrictions or quarantines, interruptions to supply chains, or when site personnel or...

Putting the Pandemic in Plain Language

The COVID-19 pandemic has brought many negative feelings to the forefront of our everyday lives, including anxiety, fear and social division, but what if we explored the new positive relationships...

SARS-CoV-2 Landscape of Repurposed Drug Trials and Key Lessons for the Future

About the Authors Saakshi Chadha, PhD is a Senior Analyst in the Health...

COVID-19: Digestive symptoms of the novel virus and implications for clinical trials

As the entire healthcare ecosystem grapples with the COVID-19 virus, more evidence surfaces every day of manifestations beyond fever, respiratory symptoms and fatigue. In fact, a recent...

Navigating new steps in how FDA is managing COVID-19 Products

Biosimilars in the time of COVID-19 and beyond

Introduction The recent COVID-19 pandemic has triggered a race for pharmaceutical companies to repurpose their commercialized drugs approved for other clinical indications to treat patients...